© 2022 MJH Life Sciences and Urology Times. All rights reserved.
© 2022 MJH Life Sciences™ and Urology Times. All rights reserved.
September 10, 2022
The addition of pembrolizumab has the potential to improve upon standard care with abiraterone acetate plus prednisone in men with metastatic castration-resistant prostate cancer.